gemcitabine has been researched along with epirubicin in 144 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (3.47) | 18.2507 |
| 2000's | 78 (54.17) | 29.6817 |
| 2010's | 52 (36.11) | 24.3611 |
| 2020's | 9 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brown, TD; Burris, HA; Havlin, KA; O'Rourke, TJ; Rodriguez, GI; Wall, JG; Weiss, GR | 1 |
| Carmichael, J; Walling, J | 1 |
| Akrivakis, C; Arning, M; Flath, B; Lüftner, D; Mergenthaler, HG; Ohnmacht, U; Possinger, K | 1 |
| Bianco, A; Bilancia, D; Carpagnano, F; Cioffi, R; Comella, G; Comella, P; De Cataldis, G; De Lena, M; Di Rienzo, G; Frasci, G; Lorusso, V; Maiorino, L; Manzione, L; Natale, M; Nicolella, G; Pacilio, C; Panza, N | 1 |
| Bareck, E; Depisch, D; Funovics, J; Hejna, M; Kornek, GV; Kovats, E; Lang, F; Miholic, J; Raderer, M; Scheithauer, W; Valencak, J | 1 |
| Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Fogli, S; Gennari, A; Orlandini, C | 1 |
| de Leede, G; Eppinga, P; Erjavec, Z; Groen, HJ; Nabers, J; Smeets, JB; Th Sleijfer, D; van Putten, JW | 1 |
| Casella, G; Costanzo, R; De Placido, G; De Vivo, R; Iodice, F; Perrone, F; Pignata, S; Ricchi, P; Tramontana, F; Tramontana, S; Varriale, E; Vernaglia, A | 1 |
| Bengala, C; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Favre, C; Greco, F; Guarneri, V; Innocenti, F; Menconi, MC; Orlandini, C; Pazzagli, I | 1 |
| Cetto, GL; Conte, P; Crino, L; Donati, S; Galligioni, E; Gennari, A; Mansutti, M; Mazzoni, F; Molino, A; Salvadori, B | 1 |
| Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E | 1 |
| Balzano, G; Di Carlo, V; Galli, L; Nicoletti, R; Panucci, MG; Passoni, P; Reni, M; Villa, E; Zerbi, A | 1 |
| Bengala, C; Conte, P; Donati, S; Gennari, A; Guarneri, V; Landucci, E; Orlandini, C; Salvadori, B | 1 |
| Carpini, RD; Fedier, A; Fink, D; Haller, U; Schwarz, VA; Walt, H | 1 |
| Beryt, M; Felber, M; Hepp, H; Kahlert, S; Konecny, G; Langer, E; Lude, S; Pegram, M; Slamon, D; Untch, M | 1 |
| Baldini, E; Bengala, C; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Fogli, S; Gennari, A; Orlandini, C; Pazzagli, I; Salvadori, B | 1 |
| Burstein, HJ; Winer, EP | 1 |
| Van Putten, JW | 1 |
| Conte, PF; Dani, D; Donati, S; Gennari, A; Giorgetti, A; Landucci, E; Mariani, G; Pisani, P; Poli, M; Puccini, G; Salvadori, B; Salvadori, PA; Sorace, O | 1 |
| Zielinski, CC | 1 |
| Dueñas, R; Fernández, M; Jaén, A; Lozano, A; Martínez, E; Medina, B; Mohedano, N; Porras, I; Sánchez-Rovira, P | 1 |
| Bruckner, HW; Kozuch, P; Petryk, M | 1 |
| Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Fogli, S; Gennari, A | 1 |
| Chiu, HC; Chu, CY; Yang, CH | 1 |
| Cini, G; De Luca Cardillo, C; Doni, L; Fioretto, LM; Fulignati, C; Mini, E; Moretti, R; Neri, B; Pantalone, D; Quattrone, A; Ribecco, AS; Scatizzi, M; Turrini, M; Zocchi, G | 1 |
| Antonuzzo, A; Chioni, A; Conte, P; Francesca, F; Galli, L; Iannopollo, M; Orlandini, C; Ricci, S; Selli, C; Vocaturo, V | 1 |
| André, T; Artru, P; Louvet, C | 1 |
| Okusaka, T | 1 |
| Heinemann, V | 1 |
| Jassem, J | 1 |
| Boezen, HM; de Leede, GP; de Vries, EG; Eppinga, P; Erjavec, Z; Groen, HJ; Kramer, H; Strijbos, JH; Van Putten, JW; Wachters, FM | 1 |
| Crucitta, E; De Lena, M; Fiore, M; Lorusso, V; Piscitelli, D; Silvestris, N | 1 |
| Amadori, D; Fabbri, F; Frassineti, GL; Gasperi Campani, A; Gunelli, R; Ricotti, L; Tesei, A; Ulivi, P; Zoli, W | 1 |
| Ahmad, I; Dritschilo, A; Gokhale, PC; Kasid, UN; Pei, J; Rahman, A; Zhang, C | 1 |
| Beryt, M; Konecny, GE; O'Callaghan, C; Pegram, MD; Pietras, R; Slamon, DJ | 1 |
| Yardley, DA | 1 |
| Miles, D; Reichardt, P | 1 |
| Bengala, C; Campani, D; Collecchi, P; Conte, PF; Donati, S; Gennari, A; Guarneri, V; Maur, M; Orlandini, C | 1 |
| Buksmaui, S; Hausmaninger, H; Heinrich, B; Höffken, K; Krejcy, K; Miller, MA; Morack, G; Possinger, K; Wallwiener, D | 1 |
| Bastert, G; Beldermann, F; Hamerla, R; Huober, J; Krauss, K; Rudlowski, C; Schneeweiss, A; Sinn, HP; Solomayer, E; von Fournier, D; Wallwiener, D | 1 |
| Poole, C | 1 |
| Bastert, G; Hamerla, R; Huober, J; Lichter, P; Schneeweiss, A; Wallwiener, D | 1 |
| Cantore, M; Caudana, R; Ceravolo, C; Comella, G; Del Freo, A; Fiorentini, G; Luppi, G; Mambrini, A; Marangolo, M; Miserocchi, L; Piazza, E; Rabbi, C; Rosati, G; Zamagni, D | 1 |
| Jansen, CF; Schalken, JA; van der Heijden, AG; Verhaegh, G; Witjes, JA | 1 |
| Advani, SH; Doval, DC; Ermisch, S; Feher, O; Jassem, J; Khoo, KS; Miller, MA; Morack, G; Roychowdhury, D; Vodvarka, P; von Minckwitz, G | 1 |
| Aldrighetti, L; Balzano, G; Bonetto, E; Bordonaro, R; Cordio, S; Di Carlo, V; Galli, L; Luppi, G; Milandri, C; Nicoletti, R; Oliani, C; Passardi, A; Passoni, P; Reni, M; Staudacher, C; Villa, E; Zerbi, A | 1 |
| Balzano, G; Bonetto, E; Di Carlo, V; Panucci, MG; Passoni, P; Reni, M; Ronzoni, M; Staudacher, C; Villa, E; Zerbi, A | 1 |
| Philip, PA | 1 |
| Hahn, M; Lauschner, I; Rudlowski, C; Schneeweiss, A; Schuetz, F; Sinn, HP; Sohn, C; von Fournier, D | 1 |
| Barlesi, F; Daurès, JP; Pujol, JL | 1 |
| Benner, A; Brors, B; Eils, R; Hahn, M; Kramer, H; Lichter, P; Rudlowski, C; Schneeweiss, A; Schuetz, F; Sinn, HP; Sohn, C; Tews, B; Thuerigen, O; Toedt, G; Warnat, P | 1 |
| Cantore, M; Capelli, P; Fiorentini, G; Iacono, C; Lombardi, M; Mambrini, A; Pacetti, P; Pagani, M; Pederzoli, P; Pulica, C; Serio, G; Torri, T | 1 |
| Budman, DR; Calabro, A | 1 |
| Battiloro, C; Caponigro, F; Danilo, R; Formato, R; Iaffaioli, RV; Illiano, A; Tortoriello, A | 1 |
| Eickhoff, A; Eickhoff, JC; Galle, PR; Hartmann, D; Jakobs, R; Martin, W; Möhler, M; Riemann, JF | 1 |
| Aitini, E; Cantore, M; Caudana, R; Ceravolo, C; Comella, G; Del Freo, A; Fiorentini, G; Luppi, G; Mambrini, A; Marangolo, M; Miserocchi, L; Piazza, E; Rosati, G; Zamagni, D | 1 |
| Balzano, G; Bonetto, E; Cereda, S; Di Carlo, V; Nicoletti, R; Passoni, P; Reni, M; Staudacher, C; Viganò, MG; Zerbi, A | 2 |
| Bonetto, E; Bordonaro, R; Cereda, S; Cordio, S; Di Carlo, V; Galli, L; Johnson, CD; Milandri, C; Passoni, P; Reni, M; Spreafico, A; Staudacher, C | 1 |
| Adorini, L; Daniel, KC; Penna, G | 1 |
| Nagaoka, S; Okabe, Y; Ono, N; Saito, F; Sata, M; Suga, H; Toyonaga, A; Tsuruta, O | 1 |
| Bozec, L; Campone, M; Diéras, V; Espié, M; Fumoleau, P; Kayitalire, L; Petit, T; Pouillart, P; Pujade-Lauraine, E; Serin, D; Viens, P | 1 |
| Chella, A; Dini, P; Fontanini, G; Lucchi, M; Melfi, F; Mussi, A; Tibaldi, C | 1 |
| Cheng, B; Liu, K; Qiu, DB; Wang, GB | 1 |
| Bartoletti, R; Cai, T; Farina, U; Mazzoli, S; Melone, F; Mondaini, N | 1 |
| Cereda, S; Galli, L; Reni, M | 1 |
| Bützow, R; Chen, DT; Desmond, RA; Hemminki, A; Kanerva, A; Raki, M; Särkioja, M | 1 |
| Aglianò, AM; Gazzaniga, P; Gradilone, A; Silvestri, I | 1 |
| Adjei, AA; Aubry, MC; Delaune, R; Foster, NR; Kardinal, CG; Maurer, MJ; Nikcevich, DA; Northfelt, DW; Okuno, SH; Rowland, KM; Sloan, JA; Soori, GS | 1 |
| Marik, PE; Vahid, B | 1 |
| Arcidiacono, PG; Balzano, G; Cereda, S; Di Carlo, V; Mazza, E; Nicoletti, R; Passoni, P; Reni, M; Staudacher, C; Zerbi, A | 1 |
| Cheng, AL; Hsu, C; Hu, FC; Huang, TC; Kuo, SH; Lin, CC; Shih, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Ansari, R; Geyer, CE; Hamm, JT; Kardinal, CG; Kim, W; Lembersky, BC; Paik, S; Rastogi, P; Raymond, JM; Robidoux, A; Shalaby, IA; Song, YK; Tseng, GC; Wilson, JW; Wolmark, N | 1 |
| Bowman, A; Coleman, RE; Dunn, JA; Earl, HM; Fernando, IN; Hiller, L; Howard, HC; Poole, CJ; Ritchie, DM; Wardley, AM | 1 |
| Hoskins, PJ | 1 |
| Arcidiacono, PG; Balzano, G; Cereda, S; Di Carlo, V; Mazza, E; Nicoletti, R; Passoni, P; Reni, M; Rognone, A; Villa, E; Zerbi, A | 1 |
| Pawlega, J; Zygulska, AL | 1 |
| Cantore, M; Del Freo, A; Mambrini, A; Orlandi, M; Pacetti, P; Pezzuolo, D; Seta, RD; Tartarini, R; Torri, T | 1 |
| Dreisbach, L; Kristedja, T; Kurtin, S; Mahadevan, D; Obregon, Y; Von Hoff, DD; Williams, D | 1 |
| Carrasco, E; Chacón, I; de la Torre-Cabrera, C; Dueñas, B; Dueñas-García, R; Fernández-Navarro, M; García-Tapiador, AM; Jaén-Morago, A; Martín-Salvago, MD; Martínez, J; Martínez-Ortega, E; Ortega-Granados, AL; Ribelles, N; Rueda, AI; Sánchez-Muñoz, A; Sánchez-Rovira, P; Tortosa, CR | 1 |
| Ceraulo, D; Cereda, S; Fugazza, C; Mazza, E; Reni, M; Rognone, A; Villa, E | 1 |
| Aldrighetti, L; Cereda, S; Nicoletti, R; Passoni, P; Reni, M; Viganò, MG; Villa, E | 1 |
| de Vries, EG; Groen, HJ; Maring, JG; Maurer, M; Uges, DR; Wachters, FM | 1 |
| Ardavanis, A; Arnogiannaki, N; Doufexis, D; Kountourakis, P; Maliou, S; Missitzis, I; Pissakas, G; Sotiropoulou, A; Zobolas, V | 1 |
| Dickson, NR; Foust, JT; Grapski, R; Hainsworth, JD; Hendricks, LK; Peacock, NW; Scott, WL; Vázquez, ER; White, MB; Yardley, DA | 1 |
| Burris, HA; Daniel, B; Hainsworth, JD; Inhorn, R; Lane, CM; Naot, Y; Vazquez, ER; Yardley, DA; Zubkus, J | 1 |
| Isufi, I; Kaley, K; Saif, MW; Syrigos, K | 1 |
| Arcuri, C; Arisi, E; Caffo, O; Caldara, A; Ferro, A; Galligioni, E; Griso, C; Murgia, V; Scalone, S; Sorio, R | 1 |
| Chu, P; DU, XL; Li, DP; Liu, NF; Lu, CH; Sheng, XG; Zhou, CX | 1 |
| Contreras Ibáñez, JA; Díaz Gómez, L; Navas García, N | 1 |
| Brodowicz, T; Loibl, S; Lück, HJ; Nekljudova, V; Schwenkglenks, M; Skacel, T; von Minckwitz, G; Zielinski, C | 1 |
| Bassi, C; Cantore, M; Fiorentini, G; Mambrini, A; Orlandi, M; Torri, T | 1 |
| Balzano, G; Belli, C; Cappio, S; Cereda, S; Doglioni, C; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rezzonico, S; Rognone, A; Slim, N; Villa, E | 1 |
| Andrieu, JM; Bats, AS; Eme, D; Hofmann, H; Huchon, C; Le Frere-Belda, MA; Lecuru, F; Levy, E; Medioni, J; Oudard, S | 1 |
| Bonnabry, P; Fleury-Souverain, S; Geiser, L; Hochstrasser, D; Nussbaumer, S; Sadeghipour, F; Veuthey, JL | 1 |
| Cortesi, E; Frati, L; Gandini, O; Gazzaniga, P; Gradilone, A; Naso, G; Nicolazzo, C; Palazzo, A; Petracca, A; Raimondi, C | 1 |
| Cao, M; Chen, HG; Ma, CK; Ma, J; Xue, W | 1 |
| Matsuo, T; Miyata, Y; Ohba, K; Sagara, Y; Sakai, H; Takahashi, H; Watanabe, S | 1 |
| Aprile, G; Balzano, G; Cereda, S; Di Carlo, V; Di Muzio, N; Fugazza, C; Magli, A; Milandri, C; Passoni, P; Reni, M; Rognone, A; Saletti, P; Tronconi, MC; Villa, E; Zerbi, A | 1 |
| Bouchardy, C; Dehler, S; Ess, S; Frick, H; Joerger, M; Konzelmann, I; Savidan, A; Thürlimann, B | 1 |
| Auriemma, A; Bassi, C; Boz, G; Cantore, M; Frigerio, I; Giardino, A; Girelli, R; Mambrini, A; Orlandi, M; Salvia, R | 1 |
| Abotouk, N; Halim, A | 1 |
| Hassali, MA; Hassan, BA; Othman, SB; Weiderpass, E; Yusoff, ZB | 1 |
| Alba-Conejo, E; de la Torre-Cabrera, C; Fernández, M; Fernández-Navarro, M; Jaén-Morago, A; Llácer, C; Lomas-Garrido, M; Navarro-Perez, V; Plata-Fernández, YM; Ramirez-Tortosa, C; Sánchez-Muñoz, A; Sánchez-Rovira, P | 1 |
| Aigner, J; Jäger, D; Lorenzo Bermejo, J; Marmé, F; Schneeweiss, A; Sinn, P; Sohn, C | 1 |
| Fujita, S; Katagata, N; Matsuzaki, M; Nomizu, T; Saito, M; Sakuma, T; Takenoshita, S; Watanabe, F | 1 |
| Alba, E; de la Torre-Cabrera, C; Fernández, M; Fernández-Navarro, M; Jaén-Morago, A; Pascual, J; Plata-Fernández, Y; Ramirez-Tortosa, C; Sánchez-Muñoz, A; Sánchez-Rovira, P | 1 |
| Alfred Witjes, J; Arentsen, HC; Falke, J; Høgset, A; Oosterwijk, E | 1 |
| Elsing, C; Hannig, CV; Herrmann, C; Herrmann, T; Jäger, D; Stremmel, W | 1 |
| Abraham, J; Caldas, C; Chan, S; Dean, S; Dunn, J; Earl, HM; Fenwick, N; Gallagher, C; Gounaris, I; Harries, M; Hickish, T; Hiller, L; Houston, S; Hughes-Davies, L; Iddawela, M; Laing, R; McAdam, K; Provenzano, E; Ritchie, D; Skene, A; Vallier, AL; Wishart, G; Young, J | 1 |
| Abdi, E; Badger, HD; Boyle, F; Bull, J; Chirgwin, J; Forbes, JF; Francis, PA; Gebski, V; Kannourakis, G; Leong, E; Lindsay, DF; McCarthy, N; Reaby, L; Simpson, A; Veillard, AS; Wilcken, N; Zannino, D; Zdenkowski, N | 1 |
| Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY | 1 |
| Chen, X; Dai, H; Qian, Z; Wang, Y; Xu, X; Zhao, Y | 1 |
| Chi, Y; Song, Y; Wang, J; Yang, L; Zhou, A | 1 |
| Ah Lee, S; Gwe Ahn, S; Jeong, J; Min Lee, H; Woo Lee, H | 1 |
| Andergassen, U; Beckmann, MW; Fasching, PA; Fehm, T; Friedl, TW; Friese, K; Hepp, P; Janni, W; Jückstock, J; Lichtenegger, W; Lorenz, R; Pantel, K; Rack, B; Schindlbeck, C; Schneeweiss, A; Tesch, H; Zwingers, T | 1 |
| Li, Y; Shang, YM; Yang, Y; Zheng, H | 1 |
| Baretton, GB; Froehner, M; Hakenberg, OW; Heberling, U; Hübler, M; Koch, R; Novotny, V; Oehlschlaeger, S; Wirth, MP | 1 |
| Balzano, G; Belli, C; Ceraulo, D; Cereda, S; Di Terlizzi, G; Doglioni, C; Dugnani, E; Falconi, M; Lampasona, V; Liberati, D; Maggiora, P; Nicoletti, R; Pasquale, V; Piemonti, L; Reni, M; Scavini, M; Sordi, V | 1 |
| du Bois, A; Grabowski, JP; Harter, P; Heitz, F; Heitz, J; Kristensen, G; Pfisterer, J; Pujade-Lauraine, E; Ray-Coquard, I; Reuss, A; Traut, A | 1 |
| Alunni-Fabbroni, M; Andergassen, U; Fasching, P; Fehm, T; Friedl, TW; Hecker, N; Hepp, P; Jäger, B; Janni, W; Lorenz, R; Rack, B; Schneeweiss, A; Trapp, E | 1 |
| Cui, H; Jiang, R; Li, X; Lin, X; Liu, C; Tao, R; Tian, S; Zhuang, H; Zhuo, C | 1 |
| Chen, CS; Cheng, CL; Chiu, KY; Ho, HC; Hung, SC; Li, JR; Ou, YC; Wang, SS; Yang, CK | 1 |
| Chung, JI; Hwang, H; Kim, TS; Noh, GH | 1 |
| Biankin, AV; Chantrill, L; Chin, V; Nagrial, A; O'Connor, CA; Scholten, RJ; Sjoquist, K; Yip, D | 1 |
| Kopeček, J; Li, L; Opanasopit, P; Soodvilai, S; Wang, J; Yang, J | 1 |
| Chang, YJ; Chen, HA; Huang, CY; Huang, MT; Makondi, PT; Wang, JW; Wei, PL | 1 |
| Chen, J; Li, Z; Pan, Z; Yao, J; Yao, Z; Zhang, Y | 1 |
| Jones, RL | 1 |
| Diao, WL; Guo, HQ; Wang, TW; Yang, R; Yuan, H; Zhao, XZ | 1 |
| Bi, PD; Duan, WJ; Liu, NQ; Ma, Y; Zhen, X | 1 |
| Alsyouf, M; Groegler, J; Hu, B; Pierorazio, P | 1 |
| Song, JX; Yuan, BS; Yuan, Y; Zhang, MN | 1 |
| Cheng, X; Li, Y; Tian, Y | 1 |
| Andergassen, U; Bauer, E; Beckmann, MW; Bekes, I; Blohmer, JU; Brucker, SY; de Gregorio, A; de Gregorio, N; Deniz, M; Fasching, PA; Fehm, TN; Fink, V; Forstbauer, H; Friedl, TWP; Häberle, L; Heinrich, G; Janni, W; Lato, K; Lorenz, R; Mahner, S; Müller, V; Rack, B; Schneeweiss, A; Schrader, I; Tesch, H | 1 |
| Cao, Y; Chu, C; Liu, Z; Lu, J; Wu, C; Zhang, Y | 1 |
| Niu, X; Wang, T; Zhong, B | 1 |
| Deva, S; Findlay, M; Hitchen, N; Lawrence, B; Waldron, NR | 1 |
| Cruz, A; de-Castro-Ríos, A; Lema-Atán, JÁ; Lendoiro, E; López-Rivadulla, M; Paniagua-González, L | 1 |
22 review(s) available for gemcitabine and epirubicin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
New anticancer agents.
Topics: Alkaloids; Animals; Antineoplastic Agents; Azacitidine; Biphenyl Compounds; Chrysenes; Deoxycytidine; Echinomycin; Epirubicin; Etanidazole; Flavonoids; Gemcitabine; Guanidines; Humans; Idarubicin; Menogaril; Mitoguazone; Neoplasms; Nitroimidazoles; Nogalamycin; Organoplatinum Compounds; Paclitaxel; Pentostatin; Polymers; Propylene Glycols; Ribavirin; Sulfonylurea Compounds; Trimetrexate; Vidarabine Phosphate | 1991 |
Advanced breast cancer: investigational role of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans | 1997 |
New combinations with epirubicin in advanced breast cancer.
Topics: Adult; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Survival Rate; Time Factors | 2001 |
New combinations with Herceptin in metastatic breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Interactions; Drug Synergism; Epirubicin; Female; Fluorouracil; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Nitriles; Organoplatinum Compounds; Paclitaxel; Tamoxifen; Thiotepa; Trastuzumab; Treatment Outcome; Triazoles; Vinblastine; Vinorelbine | 2001 |
Gemcitabine/anthracycline combinations in metastatic breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Neoadjuvant gemcitabine therapy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2002 |
A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Epirubicin; Fluorouracil; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Interferon alpha-2; Interferon-alpha; Irinotecan; Leucovorin; Multicenter Studies as Topic; Organoplatinum Compounds; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Recombinant Proteins; Respiratory Distress Syndrome; Taxoids; Treatment Outcome | 2002 |
[Gemcitabine-based combinations in inoperable pancreatic cancers].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Routes; Epirubicin; Fluorouracil; Gemcitabine; Humans; Irinotecan; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
Chemotherapy for biliary tract cancer in Japan.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Epirubicin; Fluorouracil; Gemcitabine; Humans; Japan | 2002 |
Role of gemcitabine in the treatment of advanced and metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Epirubicin; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vindesine; Vinorelbine | 2003 |
Gemcitabine and anthracyclines in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Epirubicin; Gemcitabine; Humans | 2003 |
Gemcitabine and docetaxel in metastatic and neoadjuvant treatment of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Epirubicin; Gemcitabine; Humans; Neoadjuvant Therapy; Taxoids | 2004 |
Adjuvant chemotherapy for early-stage breast cancer: the tAnGo trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Research Design; Survival Analysis | 2004 |
Experience with docetaxel in the treatment of gastric cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Epirubicin; Fluorouracil; Gemcitabine; Humans; Irinotecan; Stomach Neoplasms; Taxoids | 2005 |
Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2006 |
[Arterial infusion chemotherapy for patients with advanced pancreatic cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Celiac Artery; Deoxycytidine; Drug Administration Schedule; Epirubicin; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Mesenteric Artery, Superior; Mitomycin; Pancreatic Neoplasms; Quality of Life; Radiography; Survival Rate | 2006 |
PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Epirubicin; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Survival Rate | 2007 |
Pulmonary complications of novel antineoplastic agents for solid tumors.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bevacizumab; Deoxycytidine; Doxorubicin; Epirubicin; Etoposide; Everolimus; Gemcitabine; Humans; Lung; Lung Diseases; Mitoxantrone; Neoplasms; Pneumonia; Pyrimidines; Risk Factors; Sirolimus; Teniposide; Trastuzumab | 2008 |
Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; BCG Vaccine; Deoxycytidine; Disease Progression; Epirubicin; Female; Gemcitabine; Humans; Isoniazid; Male; Middle Aged; Mitomycin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Odds Ratio; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Chemotherapy and radiotherapy for advanced pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Epirubicin; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2018 |
Chemoablation in Urothelial Carcinoma: A Systematic Review and Future Perspectives.
Topics: Administration, Intravesical; Antineoplastic Agents; Aziridines; BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials as Topic; Cystoscopy; Deoxycytidine; Epirubicin; Ethanol; Forecasting; Gemcitabine; Humans; Indolequinones; Injections, Intralesional; Interferon-alpha; Interleukin-2; Mitomycin; Urinary Bladder Neoplasms; Urothelium | 2020 |
66 trial(s) available for gemcitabine and epirubicin
| Article | Year |
|---|---|
Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Gemcitabine; Humans; Injections, Intravenous; Middle Aged; Neoplasm Staging | 1998 |
Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Quality of Life; Vinblastine; Vindesine; Vinorelbine | 1999 |
Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Deoxycytidine; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Patient Selection; Survival Rate; Time Factors | 1999 |
The gemcitabine/epirubicin/paclitaxel combination in advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Tomography, Emission-Computed | 2000 |
Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Quality of Life | 2000 |
A phase I study of gemcitabine and epirubicin for the treatment of platinum-resistant or refractory advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epirubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Treatment Outcome | 2000 |
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Epirubicin; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Paclitaxel; Survival Analysis; Thiotepa; Treatment Outcome | 2001 |
The gemcitabine/epirubicin/paclitaxel trials in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel | 2001 |
Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Treatment Outcome | 2001 |
Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Tissue Distribution; Treatment Outcome | 2001 |
Activity of the combination of high-dose epirubicin with gemcitabine in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 2001 |
Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer.
Topics: Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Treatment Outcome | 2002 |
Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; DNA Damage; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2002 |
Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Kidney Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2002 |
First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Quality of Life; Survival Rate; Treatment Outcome | 2003 |
Gemcitabine combined with epirubicin in the treatment of patients with locally advanced or metastatic breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2004 |
Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
Neoadjuvant therapy with gemcitabine in breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Recombinant Proteins; Taxoids; Time Factors; Treatment Outcome | 2004 |
Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2004 |
First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study.
Topics: Aged; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause | 2005 |
Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Italy; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
Final results of a prospective trial of a PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2005 |
Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Darbepoetin alfa; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Erythropoietin; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Ki-67 Antigen; Middle Aged; Neutropenia; Polyethylene Glycols; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Recombinant Proteins; Taxoids; Treatment Outcome | 2005 |
Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Karnofsky Performance Status; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms | 2006 |
Phase I/II study of gemcitabine and epirubicine in stage IIIB-IV non small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Treatment Outcome | 2006 |
A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Gemcitabine; Hemoglobins; Humans; Leukocyte Count; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Platelet Count | 2006 |
Randomised trial of gemcitabine versus flec regimen given intra-arterially for patients with unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate | 2007 |
Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life | 2006 |
Gemcitabine and epirubicin in patients with metastatic breast cancer: a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; France; Gemcitabine; Humans; Infusions, Intravenous; Menopause; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2006 |
Four-modality therapy in malignant pleural mesothelioma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Epirubicin; Feasibility Studies; Female; Gemcitabine; Humans; Interleukin-2; Male; Mesothelioma; Middle Aged; Pleura; Pleural Neoplasms; Radiotherapy, Adjuvant | 2007 |
[Clinical comparison of GC regimen (gemcitabine and cisplatin) versus FEC regimen (fluorouracil, epirubicin, and cyclophosphamide) as neoadjuvant chemotherapy for breast cancer].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Staging; Remission Induction | 2007 |
Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: a dose-finding study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms | 2007 |
Study supports activity of gemcitabine in treatment of early-stage breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging | 2007 |
A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intravenous; Leukopenia; Male; Mesothelioma; Middle Aged; Neutropenia; Pleural Neoplasms; Quality of Life; Remission Induction; Ribonucleotide Reductases; Survival Rate; Thrombocytopenia; Treatment Outcome | 2008 |
PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Salvage Therapy; Survival Analysis | 2008 |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA Topoisomerases, Type II; DNA-Binding Proteins; Endonucleases; Epirubicin; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome | 2008 |
Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Gene Expression Profiling; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Patient Compliance | 2008 |
tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Heart; Heart Function Tests; Humans; Liver; Liver Function Tests; Lung; Paclitaxel; Prospective Studies; Respiratory Function Tests; Survival Rate | 2008 |
Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Failure; Treatment Outcome | 2009 |
[Assessment of the value of PEF (cisplatin, epirubicin, 5 fluorouracil) in advanced extrahepatic biliary tract and pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Cisplatin; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Prognosis; Survival Rate | 2008 |
Gemcitabine-capecitabine plus intra-arterial epirubicin-cisplatin in pretreated pancreatic cancer patients: a phase I study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Maximum Tolerated Dose; Pancreatic Neoplasms | 2009 |
Phase I study of fixed dose gemcitabine plus epirubicin in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome | 2009 |
Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: results from a phase II Trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Trastuzumab | 2010 |
Weekly epirubicin as salvage therapy in patients with gemcitabine-resistant advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Epirubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Salvage Therapy | 2009 |
Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: a multimodality approach for locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Mastectomy; Middle Aged; Neoadjuvant Therapy; Patient Selection; Radiotherapy, Adjuvant; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Taxoids; Treatment Outcome | 2010 |
A phase II trial of dose-dense neoadjuvant gemcitabine, epirubicin, and albumin-bound paclitaxel with pegfilgrastim in the treatment of patients with locally advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Polyethylene Glycols; Recombinant Proteins | 2010 |
Multicenter phase 2 study of combined gemcitabine and epirubicin as second-line treatment for patients with advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Italy; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Remission Induction; Survival Analysis; Treatment Outcome | 2010 |
[Gemcitabine based combination chemotherapy, a new salvage regimen for recurrent platinum resistant epithelial ovarian cancer].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Epirubicin; Female; Gemcitabine; Humans; Ifosfamide; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Platinum Compounds; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome; Young Adult | 2011 |
Systemic gemcitabine and capecitabine plus intra-arterial epirubicin and cisplatin as second-line chemotherapy in gemcitabine-failure pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Treatment Failure | 2011 |
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2011 |
[Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer].
Topics: Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2011 |
Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Survival Rate; Young Adult | 2012 |
Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Urinary Bladder Neoplasms | 2013 |
The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Middle Aged; Prognosis; Survival Analysis; Taxoids | 2013 |
Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Survival Rate; Trastuzumab | 2014 |
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Logistic Models; Lymphatic Metastasis; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Proportional Hazards Models; Risk Factors; Time Factors; Treatment Outcome; Tumor Burden; United Kingdom | 2014 |
Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Taxoids; Trastuzumab; Treatment Outcome | 2014 |
Circulating tumor cells predict survival in early average-to-high risk breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Immunomagnetic Separation; Kaplan-Meier Estimate; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prospective Studies; Taxoids | 2014 |
(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2016 |
Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial.
Topics: Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Mucin-1; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Taxoids | 2016 |
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Prognosis; Survival Rate; Treatment Outcome | 2020 |
56 other study(ies) available for gemcitabine and epirubicin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Hypocalcemia; Hypotension; Infusions, Intravenous; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Paclitaxel; Pancreatic Neoplasms; Platinum; Prednisone; Premedication; Retrospective Studies; Vincristine | 2001 |
Resistance to topoisomerase poisons due to loss of DNA mismatch repair.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Base Pair Mismatch; Breast Neoplasms; Carrier Proteins; Colorectal Neoplasms; Deoxycytidine; DNA Repair; DNA-Binding Proteins; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Enzyme Inhibitors; Epirubicin; Female; Gemcitabine; Humans; Intercalating Agents; Mitoxantrone; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins; Taxoids; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2001 |
Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Drug Screening Assays, Antitumor; Epirubicin; Female; Gemcitabine; Humans; Paclitaxel; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2001 |
Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Monitoring; Epirubicin; Female; Fluorodeoxyglucose F18; Gemcitabine; Glucose; Humans; Liver Neoplasms; Lung Neoplasms; Paclitaxel; Predictive Value of Tests; Radiopharmaceuticals; Remission Induction; Soft Tissue Neoplasms; Survival Analysis; Time Factors; Tomography, Emission-Computed; Treatment Outcome | 2000 |
Fixed erythrodysaesthesia plaque due to gemcitabine and epirubicin treatment.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Eruptions; Epirubicin; Erythema; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Paresthesia; Skin; Taxoids | 2002 |
Unusual response to second-line single-agent gemcitabine in locally advanced primary leiomyosarcoma of the lung: a case report.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Epirubicin; Gemcitabine; Humans; Ifosfamide; Leiomyosarcoma; Lung Neoplasms; Male; Middle Aged | 2003 |
Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Division; Cell Line, Tumor; Clinical Trials as Topic; Comet Assay; Deoxycytidine; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Epirubicin; Flow Cytometry; Gemcitabine; Humans; Inhibitory Concentration 50; Mutation; Rhodamines; Time Factors; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms | 2004 |
Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Liposomes; Male; Mice; Mice, Nude; Mitoxantrone; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-raf; Taxoids; Xenograft Model Antitumor Assays | 2004 |
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Deoxycytidine; Disease Models, Animal; DNA, Neoplasm; Docetaxel; Doxorubicin; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Floxuridine; Gemcitabine; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Paclitaxel; Proto-Oncogene Proteins; Receptor, ErbB-2; Taxoids; Transplantation, Heterologous; Trastuzumab; Tumor Stem Cell Assay; Up-Regulation; Vinblastine; Vinorelbine | 2004 |
Setting the record straight: activity of gemcitabine monotherapy for breast cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Neutropenia; Palliative Care; Randomized Controlled Trials as Topic; Treatment Outcome | 2004 |
HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Paclitaxel; Prognosis; Receptor, ErbB-2; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Treatment Outcome | 2004 |
Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coloring Agents; Combined Modality Therapy; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Hyperthermia, Induced; Indolequinones; Mitomycin; Tetrazolium Salts; Thiazoles; Urinary Bladder Neoplasms | 2005 |
Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Gene Expression Profiling; Humans; Immunohistochemistry; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Sensitivity and Specificity; Taxoids; Treatment Outcome | 2006 |
Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cytoplasm; Deoxycytidine; Diphosphonates; DNA Fragmentation; Drug Antagonism; Drug Synergism; Epirubicin; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemcitabine; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Prostatic Neoplasms; Zoledronic Acid | 2006 |
Vitamin D receptor agonists, cancer and the immune system: an intricate relationship.
Topics: Calcitriol; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Doxorubicin; Drug Synergism; Epirubicin; Gemcitabine; Humans; Molecular Structure; Receptors, Calcitriol; Structure-Activity Relationship; Urinary Bladder Neoplasms | 2006 |
[New therapeutics in the suppression of superficial bladder carcinoma].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma, Papillary; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Mitomycin; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer.
Topics: Adenocarcinoma; Adenoviridae; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Mice; Mice, SCID; Oncolytic Virotherapy; Ovarian Neoplasms; Virus Replication; Xenograft Model Antitumor Assays | 2008 |
Re: The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy.
Topics: Administration, Intravesical; Antineoplastic Agents; Combined Modality Therapy; Cystectomy; Deoxycytidine; Drug Resistance, Neoplasm; Epirubicin; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2008 |
Triple cytotoxic therapy for advanced ovarian cancer: a failed application, not a failed strategy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan; Treatment Failure | 2009 |
The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged | 2010 |
Gemcitabine and epirubicin plasma concentration-related excretion in saliva in patients with non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Saliva | 2010 |
Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; gamma-Aminobutyric Acid; Gastrointestinal Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Pregabalin | 2010 |
Mestastatic gastric cancer from malignant fibrous histiocytoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dioxoles; Docetaxel; Epirubicin; Fatal Outcome; Gemcitabine; Histiocytoma, Malignant Fibrous; Humans; Ifosfamide; Lung Neoplasms; Male; Soft Tissue Neoplasms; Spinal Neoplasms; Stomach Neoplasms; Taxoids; Tetrahydroisoquinolines; Thigh; Thoracic Vertebrae; Trabectedin | 2011 |
Wipe sampling procedure coupled to LC-MS/MS analysis for the simultaneous determination of 10 cytotoxic drugs on different surfaces.
Topics: Antineoplastic Agents; Camptothecin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Deoxycytidine; Doxorubicin; Epirubicin; Etoposide; Gemcitabine; Ifosfamide; Irinotecan; Methotrexate; Organophosphorus Compounds; Surface Properties; Tandem Mass Spectrometry; Vincristine | 2012 |
Circulating tumor cells count and characterization in a male breast cancer patient.
Topics: Breast Neoplasms, Male; Carboplatin; Carcinoma, Ductal, Breast; Cell Count; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Gemcitabine; Humans; Male; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2011 |
Effect of maintenance chemotherapy with gemcitabine and paclitaxel on recurrent squamous cell carcinoma of the bladder: a case report.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cystectomy; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Japan; Male; Methotrexate; Middle Aged; Paclitaxel; Prognosis; Recurrence; Remission Induction; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2011 |
A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Carboplatin; Confidence Intervals; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Fluorouracil; Gemcitabine; Health Services Accessibility; Humans; Logistic Models; Lymphatic Metastasis; Medication Adherence; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Odds Ratio; Paclitaxel; Receptors, Estrogen; Switzerland; Taxoids; Vinblastine; Vinorelbine | 2012 |
Combined modality treatment for patients with locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Postoperative Complications; Treatment Outcome | 2012 |
Impact of chemotherapy on hypercalcemia in breast and lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Chi-Square Distribution; Cisplatin; Cyclophosphamide; Deoxycytidine; Diphosphonates; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Hypercalcemia; Imidazoles; Linear Models; Logistic Models; Lung Neoplasms; Male; Middle Aged; Pamidronate; Parathyroid Hormone-Related Protein; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Taxoids; Young Adult; Zoledronic Acid | 2012 |
[A case of triple-negative breast cancer achieved pCR by epirubicin and cyclophosphamide(EC)therapy followed by gemcitabine plus paclitaxel combination preoperative therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Remission Induction | 2013 |
The effect of photochemical internalization of bleomycin in the treatment of urothelial carcinoma of the bladder: an in vitro study.
Topics: Animals; Antibiotics, Antineoplastic; Bleomycin; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Epirubicin; Gemcitabine; Humans; Light; Mitomycin; Photochemotherapy; Photosensitizing Agents; Porphyrins; Rats; Time Factors; Urinary Bladder Neoplasms | 2014 |
Sequential chemotherapies for advanced gastric cancer: a retrospective analysis of 111 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Germany; Hospitals, University; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Taxoids; Treatment Outcome | 2013 |
Comparison of efficacy and toxicity of first line chemotherapy with or without epirubicin for patients with advanced stage soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Deoxycytidine; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Sarcoma; Survival Rate; Young Adult | 2013 |
In vitro chemosensitivity assay of ascites in epithelial ovarian cancer.
Topics: Antineoplastic Agents; Ascites; Carboplatin; Carcinoma, Ovarian Epithelial; Coloring Agents; Deoxycytidine; Disease Progression; Drug Screening Assays, Antitumor; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Survival Rate; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2013 |
[Treatment and prognosis of 117 patients with advanced urothelial carcinoma of the bladder].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate; Thrombocytopenia; Urinary Bladder Neoplasms; Urothelium | 2014 |
In vitro chemoresponse assay based on the intrinsic subtypes in breast cancer.
Topics: Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; In Vitro Techniques; Ki-67 Antigen; Mastectomy; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2014 |
Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases.
Topics: Adenocarcinoma, Papillary; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Transitional Cell; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2014 |
Decreased Overall and Bladder Cancer-Specific Mortality with Adjuvant Chemotherapy After Radical Cystectomy: Multivariable Competing Risk Analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Epirubicin; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Methotrexate; Neoadjuvant Therapy; Risk Assessment; Survival Rate; Urinary Bladder Neoplasms; Vinblastine | 2016 |
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Topotecan; Treatment Outcome; Young Adult | 2016 |
Comparison of Efficacy of Adjuvant MEC (Methotrexate, Epirubicin and Cisplatin) and GC (Gemcitabine and Cisplatin) in Advanced Upper Tract Urothelial Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Risk Factors; Survival Rate; Urologic Neoplasms | 2017 |
Toward Better Predictions of Chemosensitivity: Comparative Study of Conventional and Simulated Chemosensitivity Tests for Bladder Cancer Cell Lines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Docetaxel; Epirubicin; Gemcitabine; Humans; Mitomycin; Urinary Bladder Neoplasms | 2017 |
Drug-free albumin-triggered sensitization of cancer cells to anticancer drugs.
Topics: Antigens, CD20; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Gemcitabine; Humans; Pyrimidines; Serum Albumin, Human | 2019 |
Glucose-Regulated Protein 94 Modulates the Response of Osteosarcoma to Chemotherapy.
Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epirubicin; Gemcitabine; Humans; Membrane Glycoproteins; Osteosarcoma; Paclitaxel | 2019 |
Polyethylenimine (PEI)-Mediated E1A Increases the Sensitivity of Hepatocellular Carcinoma Cells to Chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Docetaxel; Epirubicin; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Polyethyleneimine; Viral Proteins | 2019 |
Sarcomas and old age: few options for such a large patient population.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Epirubicin; Gemcitabine; Geriatric Assessment; Humans; Ifosfamide; Male; Prognosis; Sarcoma; Survival Rate; Trabectedin | 2019 |
Comparison of gemcitabine and anthracycline antibiotics in prevention of superficial bladder cancer recurrence.
Topics: Aged; Anthracyclines; Antineoplastic Agents; Deoxycytidine; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2019 |
MiR-512-3p regulates malignant tumor behavior and multi-drug resistance in breast cancer cells via targeting Livin.
Topics: Adaptor Proteins, Signal Transducing; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; MicroRNAs; Neoplasm Proteins | 2020 |
A multiple drug loaded, functionalized pH-sensitive nanocarrier as therapeutic and epigenetic modulator for osteosarcoma.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Deoxycytidine; Drug Combinations; Epigenesis, Genetic; Epirubicin; Gemcitabine; Hydrogen-Ion Concentration; Male; Nanocapsules; Osteosarcoma; Particle Size; Rats; Rats, Sprague-Dawley | 2020 |
Chemotherapy combined with apatinib for the treatment of desmoplastic small round cell tumors: A case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Desmoplastic Small Round Cell Tumor; Epirubicin; Gemcitabine; Humans; Male; Neoplasm Metastasis; Oncogene Proteins, Fusion; Pyridines; RNA-Binding Protein EWS; Treatment Outcome; Vincristine; WT1 Proteins | 2020 |
Impact of immunohistochemistry-based molecular subtype on predicting chemotherapy response and survival in patients with T1 stage bladder cancer after bladder-preserving treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Staging; Organ Sparing Treatments; Prognosis; Progression-Free Survival; Treatment Outcome; Urinary Bladder Neoplasms | 2021 |
Molecular classification of patients with NMIBC predicts the efficacy of intravesical chemotherapy with pirarubicin, pharmorubicin and gemcitabine-immunohistochemistry-based classification.
Topics: Administration, Intravesical; Anthracyclines; Antibiotics, Antineoplastic; Deoxycytidine; Doxorubicin; Epirubicin; Gemcitabine; Humans; Immunohistochemistry; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2022 |
Real-world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first-line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Febrile Neutropenia; Gemcitabine; Humans; Middle Aged; Palliative Care; Pancreatic Neoplasms; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2023 |
LC-MS-MS Determination of Cytostatic Drugs on Surfaces and in Urine to Assess Occupational Exposure.
Topics: Chromatography, Liquid; Cyclophosphamide; Cytostatic Agents; Epirubicin; Etoposide; Gemcitabine; Humans; Irinotecan; Occupational Exposure; Paclitaxel; Tandem Mass Spectrometry; Vinorelbine | 2023 |